Probiotics Regulating Inflammation via NLRP3 Inflammasome Modulation: A Potential Therapeutic Approach for COVID-19

被引:14
|
作者
Kasti, Arezina N. [1 ]
Synodinou, Kalliopi D. [1 ]
Pyrousis, Ioannis A. [1 ,2 ]
Nikolaki, Maroulla D. [1 ]
Triantafyllou, Konstantinos D. [3 ]
机构
[1] Attikon Univ Gen Hosp, Dept Nutr & Dietet, Athens 12462, Greece
[2] Univ Patras, Sch Med, Patras 26504, Greece
[3] Natl & Kapodistrian Univ Athens, Attikon Univ Gen Hosp, Dept Propaedeut Internal Med 2, Hepatogastroenterol Unit,Med Sch, Athens 12462, Greece
关键词
probiotics; inflammasomes; NLRP3; activation; mammalians; SARS-CoV-2; LACTIC-ACID BACTERIA; FERMENTED MILK; LACTOBACILLUS; RECOGNITION; MECHANISMS; RECEPTORS; STRAINS;
D O I
10.3390/microorganisms9112376
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Inflammasomes are cytoplasmic multiprotein complexes formed by the host's immune system as a response to microbial infection and cellular damage. Many studies have revealed various regulators of NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome activation, while it has been recently shown that NLRP3 is implicated in COVID-19 pathogenesis. At the same time, probiotics counteract the inflammatory process and modulate cytokine release, thus influencing both innate and adaptive immune systems. Herein, we review the immunomodulatory potential of probiotics on the assembly of NLRP3 inflammasome, as well as the pathophysiological mechanisms supporting the use of probiotic bacteria for SARS-CoV-2 infection management, presenting evidence from preclinical studies of the last decade: in vivo, ex vivo, and mixed trials. Data show that probiotics intake is related to NLRP3 inflammasome attenuation and lower levels of inflammation markers, highlighting the beneficial effects of probiotics on inflammatory conditions. Currently, none of the ongoing clinical trials evaluating the effectiveness of probiotics intake in humans with COVID-19 has been completed. However, evidence from preclinical studies indicates that probiotics may block virus invasion and replication through their metabolites, bacteriocins, and their ability to block Angiotensin-Converting Enzyme 2 (ACE2), and by stimulating the immune response through NLRP3 inflammasome regulation. In this review, the beneficial effects of probiotics in the inflammatory process through NLRP3 inflammasome attenuation are presented. Furthermore, probiotics may target SARS-CoV-2 both by blocking virus invasion and replication and by stimulating the immune response through NLRP3 inflammasome regulation. Heterogeneity of the results-due to, among others, different bacterial strains and their metabolites, forms, dosage, and experimental designs-indicates the need for more extensive research.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Role of NLRP3 inflammasome in diabetes and COVID-19 role of NLRP3 inflammasome in the pathogenesis and treatment of COVID-19 and diabetes NLRP3 inflammasome in diabetes and COVID-19 intervention
    Zhang, Jiayu
    Ma, Xuejing
    Liu, Fuwei
    Zhang, Deju
    Ling, Jitao
    Zhu, Zicheng
    Chen, Yixuan
    Yang, Pingping
    Yang, Yanlin
    Liu, Xiao
    Zhang, Jing
    Liu, Jianping
    Yu, Peng
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [2] The NLRP3 inflammasome and COVID-19: Activation, pathogenesis and therapeutic strategies
    Zhao, Ni
    Di, Bin
    Xu, Li-li
    CYTOKINE & GROWTH FACTOR REVIEWS, 2021, 61 : 2 - 15
  • [3] NLRP3, the inflammasome and COVID-19 infection
    Donnelly, Seamas C.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2023, 116 (07) : 477 - 477
  • [4] NLRP3 inflammasome: A joint, potential therapeutic target in management of COVID-19 and fertility problems
    Bazrafkan, Mahshid
    Hosseini, Elham
    Nazari, Mahboobeh
    Amorim, Christiani Andrade
    Sadeghi, Mohammad Reza
    JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2021, 148
  • [5] COVID-19: A Case for Inhibiting NLRP3 Inflammasome, Suppression of Inflammation with Curcumin?
    Saeedi-Boroujeni, Ali
    Mahmoudian-Sani, Mohammad-Reza
    Bahadoram, Mohammad
    Alghasi, Arash
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2021, 128 (01) : 37 - 45
  • [6] Severe COVID-19: NLRP3 Inflammasome Dysregulated
    van den Berg, Daan F.
    te Velde, Anje A.
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [7] Targeting the NLRP3 Inflammasome in Severe COVID-19
    Freeman, Tracey L.
    Swartz, Talia H.
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [8] Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications
    Potere, Nicola
    Del Buono, Marco Giuseppe
    Caricchio, Roberto
    Cremer, Paul C.
    Vecchie, Alessandra
    Porreca, Ettore
    Dalla Gasperina, Daniela
    Dentali, Francesco
    Abbate, Antonio
    Bonaventura, Aldo
    EBIOMEDICINE, 2022, 85
  • [9] Targeting autophagy regulation in NLRP3 inflammasome-mediated lung inflammation in COVID-19
    Yong, Yuan-Yuan
    Zhang, Li
    Hu, Yu-Jiao
    Wu, Jian-Ming
    Yan, Lu
    Pan, Yi-Ru
    Tang, Yong
    Yu, Lu
    Law, Betty Yuen-Kwan
    Yu, Chong-Lin
    Zhou, Jie
    Li, Mao
    Qin, Da-Lian
    Zhou, Xiao-Gang
    Wu, An-Guo
    CLINICAL IMMUNOLOGY, 2022, 244
  • [10] Insulin Reduces Inflammation by Regulating the Activation of the NLRP3 Inflammasome
    Chang, Yu-Wei
    Hung, Ling-Chien
    Chen, Yu-Cheng
    Wang, Wen-Hung
    Lin, Chun-Yu
    Tzeng, Hsin-Han
    Suen, Jau-Ling
    Chen, Yen-Hsu
    FRONTIERS IN IMMUNOLOGY, 2021, 11